Literature DB >> 16871878

Prospective analysis of prevalence, distribution, and rate of recovery of left ventricular systolic dysfunction in patients with subarachnoid hemorrhage.

Nader Banki1, Alexander Kopelnik, Poyee Tung, Michael T Lawton, Daryl Gress, Barbara Drew, Michael Dae, Elyse Foster, William Parmley, Jonathan Zaroff.   

Abstract

OBJECT: Subarachnoid hemorrhage (SAH) has been associated with cardiac injury and left ventricular (LV) dysfunction. The incidence and natural history of neurocardiogenic injury after SAH remains poorly understood. The objective of this study was to describe the incidence, time course, recovery rate, and segmental patterns of LV dysfunction after SAH.
METHODS: Echocardiography was performed three times over a 7-day period in 173 patients with SAH. The incidence of global (ejection fraction [EF] < 50%) and segmental (any regional wall-motion abnormality [RWMA]) LV dysfunction was measured. The time course of LV dysfunction was determined by comparing the prevalence of LVEF less than 50% and RWMA at 0 to 2, 3 to 5, and 6 to 8 days after SAH. The recovery rate was defined as the proportion of patients with partial or complete normalization of function. The distribution of RWMAs among 16 LV segments was also determined. An LVEF less than 50% was found in 15% of patients, and 13% had an RWMA with a normal LVEF. There was a trend toward increased dysfunction at 0 to 2 days after SAH, compared with 3 to 8 days after SAH. Recovery of LV function was observed in 66% of patients. The most frequently abnormal LV segments were the basal and middle ventricular portions of the anteroseptal and anterior walls. The apex was rarely affected.
CONCLUSIONS: Left ventricular systolic dysfunction occurs frequently after SAH and usually improves over time. The observed segmental patterns of LV dysfunction often do not correlate with coronary artery distributions.

Entities:  

Mesh:

Year:  2006        PMID: 16871878     DOI: 10.3171/jns.2006.105.1.15

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  53 in total

1.  Stress-related cardiomyopathies.

Authors:  Christian Richard
Journal:  Ann Intensive Care       Date:  2011-09-20       Impact factor: 6.925

2.  Fatal stress-induced cardiomyopathy in a young patient treated with adrenomimetics.

Authors:  Bjorn Redfors; Yangzhen Shao; Elmir Omerovic
Journal:  Clin Res Cardiol       Date:  2012-05-09       Impact factor: 5.460

Review 3.  How to increase the utilization of donor hearts?

Authors:  Maya Guglin
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

4.  Traumatic subdural haematoma with electrocardiographic abnormalities simulating myocardial infarction.

Authors:  A J H H M van Oostrom; H W Mauser; E F D Wever
Journal:  Neth Heart J       Date:  2009-10       Impact factor: 2.380

5.  [ECG changes in primary neurological disorders, systemic diseases and primary cardioymopathies].

Authors:  E Kaya; C Fischer; L Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-05-09

6.  Evaluation of cerebral-cardiac syndrome using echocardiography in a canine model of acute traumatic brain injury.

Authors:  Rong Qian; Weizhong Yang; Xiumei Wang; Zhen Xu; Xiaodong Liu; Bing Sun
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

Review 7.  Critical care management of subarachnoid hemorrhage.

Authors:  Joshua M Levine
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

8.  Broken heart syndrome, neurogenic stunned myocardium and stroke.

Authors:  Amit S Dande; Amrita S Pandit
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

Review 9.  [Elevated troponin and ECG alterations in acute ischemic stroke and subarachnoid hemorrhage].

Authors:  T Liman; M Endres
Journal:  Nervenarzt       Date:  2008-12       Impact factor: 1.214

10.  Critical care management of subarachnoid hemorrhage.

Authors:  Joshua M Levine
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.